59 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
to in-license, acquire, develop and obtain regulatory approval for new and innovative products on a cost-effective basis and to market them … & Medicaid Services (“CMS”) to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including
6-K
EX-99.1
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
segment, which is the research and development of innovative women’s reproductive, health and pregnancy therapeutics. The marketing and commercialization
6-K
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug
6-K/A
EX-99.1
OBSVF
ObsEva SA
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
. Segment information
The Group operates in one segment, which is the research and development of innovative women’s reproductive, health and pregnancy
6-K
EX-99.2
OBSVF
ObsEva SA
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
innovative new chemical entities, or NCEs, for the treatment of symptoms associated with preterm labor and improvement of clinical pregnancy and live
6-K
EX-99.1
6bq08ejtdn
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.1
2386hd8 0s1na
28 Jun 22
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
4:13pm
6-K
EX-99.1
58x71zt4j2iwkw7b
17 Jun 22
ObsEva Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:05am
6-K
EX-99.2
wxgy2yckym6m5n7c
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
xeqvix
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
pctxj7sj
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
fi7m8w96fx95 bnasql9
25 Apr 22
ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH
7:00am
6-K
EX-99.1
pjz3a3e02h uekdq8xe
22 Mar 22
Current report (foreign)
7:28am
424B7
t3vtfk1i9uxmcvbws
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
epkm28q5
17 Feb 22
Shelf registration (foreign)
4:14pm
6-K
EX-99.1
lj2od3
10 Feb 22
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
4:27pm
6-K
EX-99.1
ssu562xl
4 Feb 22
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral
4:37pm
6-K
EX-99.1
3ppriifkr50j e4k8xq
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am